Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS
0 ビュー
• 07/16/23
0
0
埋め込む
administrator
加入者
Visit http://www.ecancer.org for more
Prof Margolese (The Jewish General Hospital, McGill University, Montreal, Canada) presents, at a press conference at ASCO 2015, a federally funded phase III trial suggests that postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.
もっと見せる
フェイスブックのコメント
SORT BY-
トップコメント
-
最新のコメント